Police & Firemen s Retirement System of New Jersey Has $8.34 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Police & Firemen s Retirement System of New Jersey grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.3% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 15,877 shares of the biopharmaceutical company’s stock after purchasing an additional 651 shares during the quarter. Police & Firemen s Retirement System of New Jersey’s holdings in Regeneron Pharmaceuticals were worth $8,335,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Regeneron Pharmaceuticals by 1.3% during the first quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company’s stock worth $5,966,767,000 after buying an additional 121,545 shares during the period. Price T Rowe Associates Inc. MD boosted its position in Regeneron Pharmaceuticals by 4.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company’s stock valued at $1,379,467,000 after acquiring an additional 89,579 shares during the last quarter. Amundi grew its holdings in Regeneron Pharmaceuticals by 3.4% during the 1st quarter. Amundi now owns 1,603,901 shares of the biopharmaceutical company’s stock worth $979,794,000 after acquiring an additional 52,166 shares during the period. Goldman Sachs Group Inc. raised its position in shares of Regeneron Pharmaceuticals by 18.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company’s stock worth $724,984,000 after acquiring an additional 174,056 shares in the last quarter. Finally, American Century Companies Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 2.1% in the 1st quarter. American Century Companies Inc. now owns 722,467 shares of the biopharmaceutical company’s stock valued at $458,211,000 after purchasing an additional 14,921 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of research analyst reports. Redburn Atlantic upgraded Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Thursday, August 14th. Guggenheim lifted their price objective on shares of Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Sanford C. Bernstein increased their target price on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 27th. Citigroup lifted their price target on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Finally, Jefferies Financial Group upped their price objective on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a “buy” rating in a report on Wednesday, August 27th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $789.91.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $694.99 on Friday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $803.41. The company has a market cap of $73.04 billion, a price-to-earnings ratio of 16.64, a PEG ratio of 2.03 and a beta of 0.31. The company’s fifty day moving average price is $596.36 and its two-hundred day moving average price is $570.46. The company has a current ratio of 4.06, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The company had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. During the same period in the previous year, the firm posted $12.46 earnings per share. The firm’s revenue for the quarter was up .9% on a year-over-year basis. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 5th. Stockholders of record on Thursday, November 20th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Thursday, November 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is 8.43%.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Christine A. Poon sold 6,500 shares of the stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the completion of the sale, the director directly owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Jason Pitofsky sold 431 shares of the firm’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the transaction, the vice president owned 4,233 shares in the company, valued at approximately $2,757,503.19. This trade represents a 9.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 7.02% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.